Archives: Agenda

• Transforming Protocol to Execution: How AIKA uses advanced AI to streamline protocol generation, enhance feasibility analysis, and reduce study start-up timelines.
• Data-Driven Decision Support: Leveraging real-time operational insights and predictive analytics to improve trial performance and risk mitigation.
• Scaling Clinical Operations: Practical examples of AIKA in action, from automated task orchestration to cross-functional collaboration that drives efficiency and quality.

Don’t forget to leave us your feedback through our app! Your insights help us make future sessions even better.

• Why companies need S&OP/IBP even though they don’t have “Sales”
• How to obtain cross-functional participation and benefi ts
• How long-term planning benefi ts your supplier relationships

Many clinical supply chains treat Interactive Response Technology (IRT) as a passive transaction log rather than the strategic brain of their trial logistics. This disconnect routinely leads to rigid system setups, massive clinical waste, and exhausting, reactive “fi refi ghting” when protocols inevitably shift.
In this interactive, live-case boardroom session, four IRT specialists will break down the invisible walls between system programming and physical supply chain management. Abandoning standard PowerPoint slides, our panel will guide the room through an interactive “Trial Autopsy” to map out the critical blind spots in the clinical lifecycle.

Key Takeaways & Interactive Themes:

• Lost in Translation: How to actually communicate with your IRT vendor or internal specialists during setup so your supply rules don’t get butchered.
• The “Just in Case” Trap: Why over-buffering your site stock creates a nightmare of waste, and how to let live data do the heavy lifting instead.
• Playing Offense, Not Defense: Moving away from panicked, reactive fi xes and confi guring your IRT to spot bottlenecks weeks before a patient walks through the clinic door.

Moderator: Keaton Fonvielle, Head of Client Services, Atreo.io

• How the industry can align on responsible AI practices to guarantee end-to-end patient safety
• Deconstructing the FDA/EMA joint AI Guidance: How to promote responsible innovation while maintaining rigorous regulatory standards
• How do you actually implement AI within these strict frameworks without paralyzing your development cycles?
• Purpose-Driven AI Governance: The Importance of defining a precise context of use for AI tools to guarantee regulatory compliance, robust validation and patient safety

Moderator: Henry Ames, Co-Chair, PDA (Parenteral Drug Association) TBC